About the DAYBREAK-ALZ Study
The study will examine an oral investigational medication that may have some effect on the brain changes associated with Alzheimer’s disease. The study is designed to find out whether this investigational medication can slow down the decline in memory and mental functioning.
The DAYBREAK-ALZ study will include approximately 1,900 participants from around the globe.
There is no cost to participate. Participants will receive all study-related care, from a Specialist Physician, at no cost.
Participants may be compensated up to £14 per visit for time and travel expenses.
Who can join the DAYBREAK-ALZ Study?
To join the study, potential participants must:
Be between 55 and 85 years old
Have a close friend, relative or partner who would be willing to be a study partner throughout the study
Have experienced a gradual loss of memory over the last 6 months (the study team will assess whether this is due to Alzheimer’s disease) or have been told, by a doctor, that he or she has mild cognitive impairment (MCI) or Alzheimer’s disease
If you think you or a loved one might like to join the DAYBREAK-ALZ study or you or a loved one would like to learn more, please contact us. We can provide more information about the study and explain the details for participating. We will talk through the potential benefits and risks of being involved in the study, before you or a loved one make a decision about joining.
We will also carry out several medical checks to see whether you or a loved one are right for the study, and the study is right for you or a loved one.